Quantcast
Last updated on April 16, 2014 at 17:34 EDT

Latest CancerVax Stories

2012-12-13 08:26:07

AMES, Iowa, Dec. 13, 2012 /PRNewswire/ -- NewLink Genetics Corporation (Nasdaq: NLNK) today announced that the results of a Phase 1 dose escalation study with its proprietary HyperAcute Prostate Cancer Immunotherapy were published in the Journal of Immunotherapy. The article, entitled "Cellular Immunotherapy Study of Prostate Cancer Patients and Resulting IgG Responses to Peptide Epitopes Predicted From Prostate Tumor-associated Autoantigens," is featured in the current edition of the...

2012-12-04 08:28:02

SAN DIEGO, Dec. 04, 2012 /PRNewswire/ -- OncoSec Medical Inc. (OTCBB: ONCS), a company developing its advanced-stage ImmunoPulse DNA-based immunotherapy and NeoPulse therapy to treat solid tumor cancers, announced it will be presenting at the DNA Vaccines 2012 Conference at the Loews Coronado Bay Resort in San Diego, California. OncoSec is a Silver Sponsor of the conference. (Logo: http://photos.prnewswire.com/prnh/20110314/MM64943LOGO) The Company will conduct two presentations...

2012-10-11 07:28:26

GAITHERSBURG, Md., Oct. 11, 2012 /PRNewswire/ -- Zyngenia, Inc., a biopharmaceutical company developing Zybodies (next-generation multi-specific antibody-based drugs) in oncology and immunology, announced today that its board of directors has approved the appointment of new board members Christian Itin, Ph.D., and Jason Rhodes. Both of these executives have a deep breadth of leadership, company building and business development experience within the life sciences industry. "I am pleased to...

2012-10-09 07:26:51

SAN DIEGO, Oct. 09, 2012 /PRNewswire/ -- OncoSec Medical Inc. (OTCBB: ONCS), a company developing its advanced-stage ImmunoPulse DNA-based immunotherapy and NeoPulse therapies to treat solid tumor cancers, announced the company will be presenting data at two upcoming medical conferences. (Logo: http://photos.prnewswire.com/prnh/20120905/LA68078LOGO) Dr. Shailender Bhatia, assistant professor at the University of Washington School of Medicine, will be presenting preliminary...

2012-09-25 02:27:26

SAN DIEGO, Sept. 25, 2012 /PRNewswire/ -- OncoSec Medical Inc. (OTCBB: ONCS), a company developing its advanced-stage ImmunoPulse DNA-based immunotherapy and NeoPulse therapy to treat solid tumor cancers, announced that it has established the University of Washington (UW) as the second enrolling site for its Phase II metastatic melanoma clinical trial (OMS-I100). Investigational Review Board (IRB) approval has been received by UW, and investigators are actively recruiting for this...

2012-06-22 10:23:52

LOS ALTOS, Calif., June 22, 2012 /PRNewswire-iReach/ -- AbGenomics International announced today that it has raised $11 million in current financing round. It brings total investment in AbGenomics to approximately $52 million since its inception in 2000. (Photo: http://photos.prnewswire.com/prnh/20120622/CG29275) AbGenomics will use the proceeds to continue advancing its therapeutic antibodies for autoimmune diseases and cancers. AbGenomics' lead drug candidate AbGn-168H, a humanized...

2012-06-20 02:26:14

SAN DIEGO, June 20, 2012 /PRNewswire-iReach/ -- NovaRx Completes Enrollment in Lucanix(®) Pivotal Phase III Therapeutic Vaccine Trial for Post-frontline Maintenance Therapy in Non-small Cell Lung Cancer. (Photo: http://photos.prnewswire.com/prnh/20120620/CG26946) First Interim Analysis for NSCLC Trial in Third Quarter 2012. NovaRx Corporation announced that it has recently completed the planned enrollment in its Phase III clinical trial of Lucanix(®) (belagenpumatucel-L). Lucanix...

2012-05-17 06:25:05

WORCESTER, Mass. and TORONTO, May 17, 2012 /PRNewswire/ -- Generex Biotechnology Corporation (OTCBB: GNBT.OB) is pleased to announce today that new members have joined the Scientific Advisory Board (SAB) of its wholly-owned subsidiary, Antigen Express, Inc. for the company's AE37 breast cancer vaccine. The following distinguished investigators join Dr. Gabriel N. Hortobagyi, MD, FACP (University of Texas MD Anderson Cancer Center), Dr. Kathy D. Miller, MD (Indiana University School of...

2012-04-03 06:25:52

WORCESTER, Mass. and TORONTO, April 3, 2012 /PRNewswire/ -- Generex Biotechnology Corporation (OTCBB: GNBT.OB) announced today that the American Association for Cancer Research (AACR) chose to spotlight a presentation on data from the ongoing clinical trial of AE37, an immunotherapeutic vaccine to prevent relapse in patients who have had breast cancer being developed by Antigen Express, in a press conference. The annual AACR meeting is one of the largest national cancer conferences in the...

2012-03-06 06:05:00

HONG KONG, March 6, 2012 /PRNewswire-Asia/ -- CK Life Sciences Int'l., (Holdings) Inc. ("CK Life Sciences" or the "Company") today announced that the FDA (U.S. Food and Drug Administration) has granted clearance for its subsidiary Polynoma LLC ("Polynoma")'s Investigational new drug (IND) application, allowing it to proceed with Phase III clinical testing of its melanoma vaccine. One of A Few Asian Companies Cleared by FDA for Phase III Clinical Trial This makes CK Life Sciences one of a...